查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1603780

2030 年偏頭痛治療市場預測：按治療類型、藥物類別、給藥途徑、年齡層、嚴重程度、最終用戶和地區進行的全球分析

Migraine Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type (Pharmacological Treatments and Non-Pharmacological Treatments), Drug Class, Route Of Administration, Age Group, Severity, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球偏頭痛治療市場規模將達到 34.6 億美元，預計到 2030 年將達到 45.2 億美元，預測期內複合年成長率為 6.2%。

偏頭痛治療是指旨在緩解偏頭痛症狀並預防未來發作的醫療策略。治療選擇包括急性治療，如鎮痛藥（非類固醇抗發炎藥、曲坦類藥物和鎮痛藥）和預防性治療，如BETA阻斷劑、抗驚厥藥和抗憂鬱症。

據偏頭痛研究基金會稱，偏頭痛是世界上第三大常見疾病，影響全球約 10 億人。

偏頭痛盛行率增加

隨著越來越多的人經常或長期遭受偏頭痛，對有效治療方法的需求增加，從而導致市場不斷擴大。壓力、生活方式的改變和意識的提高等因素導致全球偏頭痛患者的增加。不斷成長的患者數量正在推動製藥公司開發創新治療方法，包括新藥、設備和治療方法。此外，人們對治療選擇的認知不斷提高，導致醫療保健提供者提供專門的治療，進一步增加了偏頭痛急性和預防性治療的市場需求。

偏頭痛藥物的副作用

偏頭痛藥物的副作用，如噁心、頭暈、疲勞和潛在的心血管問題，可能會妨礙患者遵守治療計畫。曲坦類藥物和某些預防藥物可能會產生副作用，對某些人來說可能會超過其益處。由於需要替代治療，此類副作用可能會導致處方治療的停止、療效下降以及醫療費用增加。這限制了某些藥物的吸收並阻礙了偏頭痛治療市場。

虛擬諮詢越來越受歡迎

遠端醫療允許患者，特別是在偏遠和服務欠缺地區的患者，無需親自前往醫療機構即可諮詢醫療保健專業人員。這對於需要定期後續觀察、藥物調整和治療計劃指導的偏頭痛患者尤其有益。虛擬就診可以及時診斷並開立 CGRP 抑制劑和其他偏頭痛特異性治療藥物等藥物處方，從而提高治療依從性並減少醫療保健障礙。數位健康工具的整合進一步支援個人化醫療並推動市場擴張。

抗治療性

當患者因遺傳因素、藥物過度使用或身體隨著時間的推移對治療的適應方式而對標準治療沒有反應時，就會出現偏頭痛藥物的抗治療性。這種抗治療性導致患者不滿並增加對替代療法的需求。它還增加了醫療保健成本，因為在發現治療方法有效之前必須嘗試多種治療方法。此外，抗治療性可能會阻止新患者接受治療，從而影響市場成長和治療依從性。

COVID-19 的影響

COVID-19 大流行對偏頭痛治療市場產生了重大影響，導致醫療服務中斷、醫療程序延誤以及前往治療中心的機會有限。停工和壓力增加增加了偏頭痛的發生率，但許多患者在接受治療時面臨困難。遠端醫療已成為重要的解決方案，可以透過虛擬諮詢來開藥。儘管面臨這些挑戰，市場對數位健康解決方案和家庭偏頭痛管理方案的需求不斷成長，從而塑造了疫情後的未來治療趨勢。

慢性偏頭痛領域預計在預測期內規模最大

預計慢性偏頭痛細分市場將在整個預測期內獲得最大的市場佔有率。慢性偏頭痛治療的重點是控制每月發生超過 15 天的頻繁且持久的偏頭痛發作。通常會採用 CGRP 抑制劑、肉毒桿菌注射、抗驚厥藥物和BETA阻斷劑預防性治療來降低發作頻率和嚴重程度。此外，早期療育可以防止陣發性偏頭痛發展為慢性偏頭痛，這對患者俱有顯著的健康和經濟效益。

預計神經科在預測期內將經歷最高的複合年成長率。

預計神經科在預測期內將經歷最高的複合年成長率。神經科的偏頭痛治療涉及全面的方法，包括準確的診斷、個人化的治療計劃和持續的管理。神經科提供準確的診斷、最新的治療方案以及對慢性和重症病例的專家管理。這種專門的治療可以提高治療效果，減少偏頭痛頻率，並提高患者的整體生活品質。

比最大的地區

由於意識的提高、獲得醫療保健的機會的增加以及偏頭痛相關疾病盛行率的增加，預計亞太地區將在預測期內創下最大的市場佔有率。快速的都市化、高壓力水平和生活方式的改變導致偏頭痛患者增加。中國、印度和日本等國家對急性和預防性治療（包括藥物、治療和設備）的需求不斷增加。該市場得到政府措施和全部區域醫療基礎設施改善的進一步支持。

複合年成長率最高的地區：

由於認知度高、醫療基礎設施先進以及偏頭痛盛行率不斷上升，預計北美在預測期內的複合年成長率最高。由於 CGRP 抑制劑、肉毒桿菌注射和數位療法等創新治療方法的出現，美國和加拿大的市場正在擴大。該市場也受益於遠端醫療的普及和個人化醫療的增加。主要企業正在專注於新型治療和預防解決方案，以滿足該地區不斷變化的需求。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球偏頭痛治療市場：依治療類型

  • 藥物治療
    • 早期預防醫學
    • 預防醫學
    • 非處方藥
  • 非藥物治療
    • 行為療法
    • 針刺
    • 經顱磁刺激（TMS）
    • 深部腦部刺激（DBS）
    • 神經阻斷
    • 放鬆技巧

第6章全球偏頭痛治療市場：依藥物類別

  • 曲普坦
  • 麥角胺衍生物
  • 抑鈣素基因相關胜肽 (CGRP) 抑制劑
  • 抗憂鬱症和抗癲癇藥
  • 肉毒桿菌毒素
  • BETA受體阻斷劑
  • 鈣離子通道阻斷劑
  • 其他藥物類別

第7章全球偏頭痛治療市場：依給藥途徑

  • 口服
  • 注射
  • 鼻內
  • 經皮的

第8章全球偏頭痛治療市場：依年齡層

  • 兒科的
  • 成人
  • 進階的

第9章全球偏頭痛治療市場：依嚴重程度

  • 慢性偏頭痛
  • 陣發性偏頭痛

第10章全球偏頭痛治療市場：依最終用戶分類

  • 全科醫生
  • 神經科
  • 家庭護理設置
  • 療養院
  • 其他最終用戶

第11章全球偏頭痛治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章 公司概況

  • Amgen Inc.
  • Eli Lilly and Co.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Allergan
  • Sanofi SA
  • Merck & Co., Inc.
  • Dr. Reddy's Laboratories
  • Cipla Limited
  • Mylan NV
  • Satsuma Pharmaceuticals Inc.
  • Biohaven Pharmaceutical Holding Company
  • Lundbeck A/S
  • Atogepant
  • Zosano Pharma Corporation
  • Kalydor
Product Code: SMRC27802

According to Stratistics MRC, the Global Migraine Treatment Market is accounted for $3.46 billion in 2024 and is expected to reach $4.52 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Migraine treatment refers to medical strategies aimed at relieving the symptoms and preventing future attacks of migraine headaches, which are characterized by intense, recurring pain often accompanied by nausea, vomiting, and sensitivity to light and sound. Treatment options include acute treatments, such as pain relief medications (NSAIDs, triptans, or painkillers), and preventive treatments, like beta-blockers, anticonvulsants, or antidepressants.

According to the Migraine Research Foundation, migraine is the third most common disease in the world, affecting an estimated 1 billion people globally.

Market Dynamics:

Driver:

Rising prevalence of migraines

As more individuals experience frequent or chronic migraines, there is a greater demand for effective treatments, leading to market expansion. Factors such as stress, lifestyle changes, and increasing awareness contribute to the growing number of migraine sufferers globally. This increased patient population encourages pharmaceutical companies to develop innovative treatments, including new medications, devices, and therapies. Additionally, the rising awareness about treatment options prompts healthcare providers to offer specialized care, further fueling market demand for both acute and preventive migraine treatments.

Restraint:

Adverse effects of migraine drugs

Adverse effects of migraine drugs, such as nausea, dizziness, fatigue, and potential cardiovascular issues, can discourage patient adherence to treatment plans. Medications like triptans and certain preventive drugs may cause side effects that outweigh their benefits for some individuals. These adverse reactions can lead to discontinuation of prescribed treatments, reduced efficacy, and increased healthcare costs due to the need for alternative therapies. This hampers the migraine treatment market by limiting the widespread use of certain drugs.

Opportunity:

Rising popularity of virtual consultations

Telemedicine allows individuals, especially in remote or underserved areas, to consult with healthcare professionals without the need for in-person visits. This is particularly beneficial for migraine patients who require regular follow-ups, medication adjustments, and guidance on treatment plans. Virtual consultations enable timely diagnosis and prescription of medications, such as CGRP inhibitors or other migraine-specific treatments, thus enhancing treatment adherence and reducing healthcare barriers. The integration of digital health tools further supports personalized care, fueling market expansion.

Threat:

Treatment resistance

Treatment resistance in migraine drugs occurs when patients do not respond to standard therapies, which can be due to genetic factors, medication overuse, or the body's adaptation to treatments over time. This resistance leads to patient dissatisfaction and increased demand for alternative therapies. It also drives up healthcare costs, as patients may need to try multiple treatments before finding one that works. Additionally, treatment resistance may deter new patients from seeking care, impacting market growth and treatment adherence.

Covid-19 Impact

The covid-19 pandemic significantly impacted the migraine treatment market, with disruptions in healthcare services, delays in medical procedures, and limited access to treatment centers. Lockdowns and increased stress led to a rise in migraine occurrences, yet many patients faced difficulties in obtaining treatments. Telemedicine emerged as a key solution, allowing virtual consultations for prescribing medications. Despite these challenges, the market saw growth in demand for digital health solutions and at-home migraine management options, shaping future treatment trends post-pandemic.

The chronic migraine segment is expected to be the largest during the forecast period

The chronic migraine segment is predicted to secure the largest market share throughout the forecast period. In chronic migraine treatment, the focus is on managing frequent, long-lasting migraine attacks occurring at least 15 days per month. Preventive treatments, such as CGRP inhibitors, Botox injections, anticonvulsants, and beta-blockers, are commonly prescribed to reduce the frequency and severity of attacks. Additionally, early intervention can prevent the progression of episodic migraines to chronic forms, offering significant health and economic benefits for patients.

The neurologists segment is expected to have the highest CAGR during the forecast period

The neurologists segment is anticipated to witness the highest CAGR during the forecast period. Migraine treatment by neurologists involves a comprehensive approach, including accurate diagnosis, personalized treatment plans, and ongoing management. They provide precise diagnosis, access to the latest treatment options, and expert management of chronic or severe cases. This specialized care improves treatment efficacy, reduces migraine frequency, and enhances overall quality of life for patients.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period due to increasing awareness, rising healthcare access, and a growing prevalence of migraine-related conditions. Rapid urbanization, high stress levels, and changing lifestyles contribute to a rise in migraine cases. Countries like China, India, and Japan are seeing rising demand for both acute and preventive treatments, including medications, therapies, and devices. The market is further supported by government initiatives and improving healthcare infrastructure across the region.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period driven by high awareness, advanced healthcare infrastructure, and increasing migraine prevalence. In the U.S. and Canada, the market is expanding due to the availability of innovative treatments, including CGRP inhibitors, botox injections, and digital therapeutics. The market also benefits from growing telemedicine adoption and access to personalized care. Key players are focusing on novel therapies and preventative solutions to meet the region's evolving needs.

Key players in the market

Some of the key players profiled in the Migraine Treatment Market include Amgen Inc., Eli Lilly and Co., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Allergan, Sanofi S.A., Merck & Co., Inc., Dr. Reddy's Laboratories, Cipla Limited, Mylan N.V., Satsuma Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company, Lundbeck A/S, Atogepant, Zosano Pharma Corporation and Kalydor.

Key Developments:

In November 2023, Dr. Reddy's Laboratories launched Nerivio, a state-of-the-art United States Food and Drug Administration (USFDA) approved wearable therapy device for drug-free management of migraine, in the domestic market. It is to be used within 60 minutes of onset of headache for acute treatment of migraine or every alternate day.

In March 2023, Pfizer announced that it has received FDA approval for Zavegepant, a CGRP receptor antagonist nasal spray, marking the first nasal spray in this category for acute migraine treatment. It offers a fast-acting solution, with studies showing significant improvements in pain relief within 2 hours of use.

Treatment Types Covered:

  • Pharmacological Treatments
  • Non-Pharmacological Treatments

Drug Classes Covered:

  • Triptans
  • Ergotamine Derivatives
  • Calcitonin Gene-Related Peptide (CGRP) Inhibitors
  • Anti-depressants & Anti-epileptic Drugs
  • Botulinum Toxin
  • Beta-blockers
  • Calcium Channel Blockers
  • Other Drug Classes

Route Of Administrations Covered:

  • Oral
  • Injection
  • Intranasal
  • Transdermal

Age Groups Covered:

  • Pediatric
  • Adult
  • Geriatric

Severities Covered:

  • Chronic Migraine
  • Episodic Migraine

End Users Covered:

  • General Practitioners
  • Neurologists
  • Homecare Settings
  • Nursing Homes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Migraine Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Pharmacological Treatments
    • 5.2.1 Abortive Medications
    • 5.2.2 Preventive Medications
    • 5.2.3 Over-the-counter Medications
  • 5.3 Non-Pharmacological Treatments
    • 5.3.1 Behavioral Therapy
    • 5.3.2 Acupuncture
    • 5.3.3 Transcranial Magnetic Stimulation (TMS)
    • 5.3.4 Deep Brain Stimulation (DBS)
    • 5.3.5 Nerve Blocks
    • 5.3.6 Relaxation Techniques

6 Global Migraine Treatment Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Triptans
  • 6.3 Ergotamine Derivatives
  • 6.4 Calcitonin Gene-Related Peptide (CGRP) Inhibitors
  • 6.5 Anti-depressants & Anti-epileptic Drugs
  • 6.6 Botulinum Toxin
  • 6.7 Beta-blockers
  • 6.8 Calcium Channel Blockers
  • 6.9 Other Drug Classes

7 Global Migraine Treatment Market, By Route Of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injection
  • 7.4 Intranasal
  • 7.5 Transdermal

8 Global Migraine Treatment Market, By Age Group

  • 8.1 Introduction
  • 8.2 Pediatric
  • 8.3 Adult
  • 8.4 Geriatric

9 Global Migraine Treatment Market, By Severity

  • 9.1 Introduction
  • 9.2 Chronic Migraine
  • 9.3 Episodic Migraine

10 Global Migraine Treatment Market, By End User

  • 10.1 Introduction
  • 10.2 General Practitioners
  • 10.3 Neurologists
  • 10.4 Homecare Settings
  • 10.5 Nursing Homes
  • 10.6 Other End Users

11 Global Migraine Treatment Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Amgen Inc.
  • 13.2 Eli Lilly and Co.
  • 13.3 AbbVie Inc.
  • 13.4 Teva Pharmaceutical Industries Ltd.
  • 13.5 Novartis AG
  • 13.6 Pfizer Inc.
  • 13.7 Johnson & Johnson
  • 13.8 GlaxoSmithKline plc
  • 13.9 Allergan
  • 13.10 Sanofi S.A.
  • 13.11 Merck & Co., Inc.
  • 13.12 Dr. Reddy's Laboratories
  • 13.13 Cipla Limited
  • 13.14 Mylan N.V.
  • 13.15 Satsuma Pharmaceuticals Inc.
  • 13.16 Biohaven Pharmaceutical Holding Company
  • 13.17 Lundbeck A/S
  • 13.18 Atogepant
  • 13.19 Zosano Pharma Corporation
  • 13.20 Kalydor

List of Tables

  • Table 1 Global Migraine Treatment Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Migraine Treatment Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 3 Global Migraine Treatment Market Outlook, By Pharmacological Treatments (2022-2030) ($MN)
  • Table 4 Global Migraine Treatment Market Outlook, By Abortive Medications (2022-2030) ($MN)
  • Table 5 Global Migraine Treatment Market Outlook, By Preventive Medications (2022-2030) ($MN)
  • Table 6 Global Migraine Treatment Market Outlook, By Over-the-counter Medications (2022-2030) ($MN)
  • Table 7 Global Migraine Treatment Market Outlook, By Non-Pharmacological Treatments (2022-2030) ($MN)
  • Table 8 Global Migraine Treatment Market Outlook, By Behavioral Therapy (2022-2030) ($MN)
  • Table 9 Global Migraine Treatment Market Outlook, By Acupuncture (2022-2030) ($MN)
  • Table 10 Global Migraine Treatment Market Outlook, By Transcranial Magnetic Stimulation (TMS) (2022-2030) ($MN)
  • Table 11 Global Migraine Treatment Market Outlook, By Deep Brain Stimulation (DBS) (2022-2030) ($MN)
  • Table 12 Global Migraine Treatment Market Outlook, By Nerve Blocks (2022-2030) ($MN)
  • Table 13 Global Migraine Treatment Market Outlook, By Relaxation Techniques (2022-2030) ($MN)
  • Table 14 Global Migraine Treatment Market Outlook, By Drug Class (2022-2030) ($MN)
  • Table 15 Global Migraine Treatment Market Outlook, By Triptans (2022-2030) ($MN)
  • Table 16 Global Migraine Treatment Market Outlook, By Ergotamine Derivatives (2022-2030) ($MN)
  • Table 17 Global Migraine Treatment Market Outlook, By Calcitonin Gene-Related Peptide (CGRP) Inhibitors (2022-2030) ($MN)
  • Table 18 Global Migraine Treatment Market Outlook, By Anti-depressants & Anti-epileptic Drugs (2022-2030) ($MN)
  • Table 19 Global Migraine Treatment Market Outlook, By Botulinum Toxin (2022-2030) ($MN)
  • Table 20 Global Migraine Treatment Market Outlook, By Beta-blockers (2022-2030) ($MN)
  • Table 21 Global Migraine Treatment Market Outlook, By Calcium Channel Blockers (2022-2030) ($MN)
  • Table 22 Global Migraine Treatment Market Outlook, By Other Drug Classes (2022-2030) ($MN)
  • Table 23 Global Migraine Treatment Market Outlook, By Route Of Administration (2022-2030) ($MN)
  • Table 24 Global Migraine Treatment Market Outlook, By Oral (2022-2030) ($MN)
  • Table 25 Global Migraine Treatment Market Outlook, By Injection (2022-2030) ($MN)
  • Table 26 Global Migraine Treatment Market Outlook, By Intranasal (2022-2030) ($MN)
  • Table 27 Global Migraine Treatment Market Outlook, By Transdermal (2022-2030) ($MN)
  • Table 28 Global Migraine Treatment Market Outlook, By Age Group (2022-2030) ($MN)
  • Table 29 Global Migraine Treatment Market Outlook, By Pediatric (2022-2030) ($MN)
  • Table 30 Global Migraine Treatment Market Outlook, By Adult (2022-2030) ($MN)
  • Table 31 Global Migraine Treatment Market Outlook, By Geriatric (2022-2030) ($MN)
  • Table 32 Global Migraine Treatment Market Outlook, By Severity (2022-2030) ($MN)
  • Table 33 Global Migraine Treatment Market Outlook, By Chronic Migraine (2022-2030) ($MN)
  • Table 34 Global Migraine Treatment Market Outlook, By Episodic Migraine (2022-2030) ($MN)
  • Table 35 Global Migraine Treatment Market Outlook, By End User (2022-2030) ($MN)
  • Table 36 Global Migraine Treatment Market Outlook, By General Practitioners (2022-2030) ($MN)
  • Table 37 Global Migraine Treatment Market Outlook, By Neurologists (2022-2030) ($MN)
  • Table 38 Global Migraine Treatment Market Outlook, By Homecare Settings (2022-2030) ($MN)
  • Table 39 Global Migraine Treatment Market Outlook, By Nursing Homes (2022-2030) ($MN)
  • Table 40 Global Migraine Treatment Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.